APO Research
Talk to an analyst

APO RESEARCH · REPORT

Vulvar and Vaginal Atrophy Therapy

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Vulvar and Vaginal Atrophy Therapy Market Analysis and Forecast 2026-2032

31 December 2025196 pages

Choose your research edition.

Industry ResearchVulvar and Vaginal Atrophy Therapy Industry Research Report 2026115 pages · $2,950 USDIndustry Growth & TrendsGlobal Vulvar and Vaginal Atrophy Therapy Industry Growth and Trends Forecast to 203291 pages · $3,450 USDMarket StructureGlobal Vulvar and Vaginal Atrophy Therapy Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032184 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Vulvar and Vaginal Atrophy Therapy Market Outlook and Growth Opportunities 2026198 pages · $4,250 USDMarket Analysis & ForecastGlobal Vulvar and Vaginal Atrophy Therapy Market Analysis and Forecast 2026-2032196 pages · $4,950 USD

Market perspective

The global Vulvar and Vaginal Atrophy Therapy market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for Vulvar and Vaginal Atrophy Therapy is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Vulvar and Vaginal Atrophy Therapy is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Vulvar and Vaginal Atrophy Therapy is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Vulvar and Vaginal Atrophy Therapy is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global manufacturers of Vulvar and Vaginal Atrophy Therapy include Viveve, VenusConcept, ThermiGen LLC, Lutronic, Hologic, Fotona, BTL Group of Companies, Almirall and Alma Lasers, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Vulvar and Vaginal Atrophy Therapy, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Vulvar and Vaginal Atrophy Therapy, also provides the sales of main regions and countries. Of the upcoming market potential for Vulvar and Vaginal Atrophy Therapy, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Vulvar and Vaginal Atrophy Therapy sales, revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Vulvar and Vaginal Atrophy Therapy market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2021 to 2032. Evaluation and forecast the market size for Vulvar and Vaginal Atrophy Therapy sales, projected growth trends, production technology, application and end-user industry.

Vulvar and Vaginal Atrophy Therapy Segment by Company

Viveve

VenusConcept

ThermiGen LLC

Lutronic

Hologic

Fotona

BTL Group of Companies

Almirall

Alma Lasers

Vulvar and Vaginal Atrophy Therapy Segment by Type

Vulvar Atrophy Therapy

Vaginal Atrophy Therapy

Vulvar and Vaginal Atrophy Therapy Segment by Application

Specialty Clinics

Hospitals

Ambulatory Surgical Centers

Others

Vulvar and Vaginal Atrophy Therapy Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Colombia

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Vulvar and Vaginal Atrophy Therapy market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Vulvar and Vaginal Atrophy Therapy and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Vulvar and Vaginal Atrophy Therapy.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Sales (consumption), revenue of Vulvar and Vaginal Atrophy Therapy in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.

Chapter 4: Detailed analysis of Vulvar and Vaginal Atrophy Therapy manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Vulvar and Vaginal Atrophy Therapy sales, revenue, price, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, sales, and revenue for each segment.

Chapter 9: Europe by type, by application and by country, sales, and revenue for each segment.

Chapter 10: China type, by application, sales, and revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, sales, and revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, sales, and revenue for each segment.

Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.

Chapter 14: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Vulvar and Vaginal Atrophy Therapy Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Vulvar Atrophy Therapy Major Manufacturers Table 3. Vaginal Atrophy Therapy Major Manufacturers Table 4. Global Vulvar and Vaginal Atrophy Therapy Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 5. Specialty Clinics Major Manufacturers Table 6. Hospitals Major Manufacturers Table 7. Ambulatory Surgical Centers Major Manufacturers Table 8. Others Major Manufacturers Table 9. Vulvar and Vaginal Atrophy Therapy Industry Trends Table 10. Vulvar and Vaginal Atrophy Therapy Industry Drivers Table 11. Vulvar and Vaginal Atrophy Therapy Industry Opportunities and Challenges Table 12. Vulvar and Vaginal Atrophy Therapy Industry Restraints Table 13. Global Vulvar and Vaginal Atrophy Therapy Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 14. Global Vulvar and Vaginal Atrophy Therapy Revenue by Region (2021-2026) & (US$ Million) Table 15. Global Vulvar and Vaginal Atrophy Therapy Revenue by Region (2027-2032) & (US$ Million) Table 16. Global Vulvar and Vaginal Atrophy Therapy Revenue Market Share by Region (2021-2026) Table 17. Global Vulvar and Vaginal Atrophy Therapy Revenue Market Share by Region (2027-2032) Table 18. Global Vulvar and Vaginal Atrophy Therapy Sales Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (K Units) Table 19. Global Vulvar and Vaginal Atrophy Therapy Sales by Region (2021-2026) & (K Units) Table 20. Global Vulvar and Vaginal Atrophy Therapy Sales by Region (2027-2032) & (K Units) Table 21. Global Vulvar and Vaginal Atrophy Therapy Sales Market Share by Region (2021-2026) Table 22. Global Vulvar and Vaginal Atrophy Therapy Sales Market Share by Region (2027-2032) Table 23. Global Vulvar and Vaginal Atrophy Therapy Revenue by Manufacturers (US$ Million) & (2021-2026) Table 24. Global Vulvar and Vaginal Atrophy Therapy Revenue Market Share by Manufacturers (2021-2026) Table 25. Global Vulvar and Vaginal Atrophy Therapy Sales by Manufacturers (US$ Million) & (2021-2026) Table 26. Global Vulvar and Vaginal Atrophy Therapy Sales Market Share by Manufacturers (2021-2026) Table 27. Global Vulvar and Vaginal Atrophy Therapy Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 28. Global Vulvar and Vaginal Atrophy Therapy Key Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 29. Global Vulvar and Vaginal Atrophy Therapy Key Manufacturers Manufacturing Sites & Headquarters Table 30. Global Vulvar and Vaginal Atrophy Therapy Manufacturers, Product Type & Application Table 31. Global Vulvar and Vaginal Atrophy Therapy Manufacturers' Establishment Date Table 32. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 33. Global Vulvar and Vaginal Atrophy Therapy by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 34. Global Vulvar and Vaginal Atrophy Therapy Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 35. Global Vulvar and Vaginal Atrophy Therapy Revenue by Type (2021-2026) & (US$ Million) Table 36. Global Vulvar and Vaginal Atrophy Therapy Revenue by Type (2027-2032) & (US$ Million) Table 37. Global Vulvar and Vaginal Atrophy Therapy Revenue Market Share by Type (2021-2026) Table 38. Global Vulvar and Vaginal Atrophy Therapy Revenue Market Share by Type (2027-2032) Table 39. Global Vulvar and Vaginal Atrophy Therapy Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 40. Global Vulvar and Vaginal Atrophy Therapy Sales by Type (2021-2026) & (K Units) Table 41. Global Vulvar and Vaginal Atrophy Therapy Sales by Type (2027-2032) & (K Units) Table 42. Global Vulvar and Vaginal Atrophy Therapy Sales Market Share by Type (2021-2026) Table 43. Global Vulvar and Vaginal Atrophy Therapy Sales Market Share by Type (2027-2032) Table 44. Global Vulvar and Vaginal Atrophy Therapy Price by Type (2021-2026) & (US$/Unit) Table 45. Global Vulvar and Vaginal Atrophy Therapy Price by Type (2027-2032) & (US$/Unit) Table 46. Global Vulvar and Vaginal Atrophy Therapy Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 47. Global Vulvar and Vaginal Atrophy Therapy Revenue by Application (2021-2026) & (US$ Million) Table 48. Global Vulvar and Vaginal Atrophy Therapy Revenue by Application (2027-2032) & (US$ Million) Table 49. Global Vulvar and Vaginal Atrophy Therapy Revenue Market Share by Application (2021-2026) Table 50. Global Vulvar and Vaginal Atrophy Therapy Revenue Market Share by Application (2027-2032) Table 51. Global Vulvar and Vaginal Atrophy Therapy Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 52. Global Vulvar and Vaginal Atrophy Therapy Sales by Application (2021-2026) & (K Units) Table 53. Global Vulvar and Vaginal Atrophy Therapy Sales by Application (2027-2032) & (K Units) Table 54. Global Vulvar and Vaginal Atrophy Therapy Sales Market Share by Application (2021-2026) Table 55. Global Vulvar and Vaginal Atrophy Therapy Sales Market Share by Application (2027-2032) Table 56. Global Vulvar and Vaginal Atrophy Therapy Price by Application (2021-2026) & (US$/Unit) Table 57. Global Vulvar and Vaginal Atrophy Therapy Price by Application (2027-2032) & (US$/Unit) Table 58. Viveve Company Information Table 59. Viveve Business Overview Table 60. Viveve Vulvar and Vaginal Atrophy Therapy Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 61. Viveve Vulvar and Vaginal Atrophy Therapy Product Portfolio Table 62. Viveve Recent Development Table 63. VenusConcept Company Information Table 64. VenusConcept Business Overview Table 65. VenusConcept Vulvar and Vaginal Atrophy Therapy Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 66. VenusConcept Vulvar and Vaginal Atrophy Therapy Product Portfolio Table 67. VenusConcept Recent Development Table 68. ThermiGen LLC Company Information Table 69. ThermiGen LLC Business Overview Table 70. ThermiGen LLC Vulvar and Vaginal Atrophy Therapy Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 71. ThermiGen LLC Vulvar and Vaginal Atrophy Therapy Product Portfolio Table 72. ThermiGen LLC Recent Development Table 73. Lutronic Company Information Table 74. Lutronic Business Overview Table 75. Lutronic Vulvar and Vaginal Atrophy Therapy Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 76. Lutronic Vulvar and Vaginal Atrophy Therapy Product Portfolio Table 77. Lutronic Recent Development Table 78. Hologic Company Information Table 79. Hologic Business Overview Table 80. Hologic Vulvar and Vaginal Atrophy Therapy Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 81. Hologic Vulvar and Vaginal Atrophy Therapy Product Portfolio Table 82. Hologic Recent Development Table 83. Fotona Company Information Table 84. Fotona Business Overview Table 85. Fotona Vulvar and Vaginal Atrophy Therapy Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 86. Fotona Vulvar and Vaginal Atrophy Therapy Product Portfolio Table 87. Fotona Recent Development Table 88. BTL Group of Companies Company Information Table 89. BTL Group of Companies Business Overview Table 90. BTL Group of Companies Vulvar and Vaginal Atrophy Therapy Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 91. BTL Group of Companies Vulvar and Vaginal Atrophy Therapy Product Portfolio Table 92. BTL Group of Companies Recent Development Table 93. Almirall Company Information Table 94. Almirall Business Overview Table 95. Almirall Vulvar and Vaginal Atrophy Therapy Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 96. Almirall Vulvar and Vaginal Atrophy Therapy Product Portfolio Table 97. Almirall Recent Development Table 98. Alma Lasers Company Information Table 99. Alma Lasers Business Overview Table 100. Alma Lasers Vulvar and Vaginal Atrophy Therapy Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 101. Alma Lasers Vulvar and Vaginal Atrophy Therapy Product Portfolio Table 102. Alma Lasers Recent Development Table 103. North America Vulvar and Vaginal Atrophy Therapy Revenue by Type (2021-2026) & (US$ Million) Table 104. North America Vulvar and Vaginal Atrophy Therapy Revenue by Type (2027-2032) & (US$ Million) Table 105. North America Vulvar and Vaginal Atrophy Therapy Sales by Type (2021-2026) & (K Units) Table 106. North America Vulvar and Vaginal Atrophy Therapy Sales by Type (2027-2032) & (K Units) Table 107. North America Vulvar and Vaginal Atrophy Therapy Sales Price by Type (2021-2026) & (US$/Unit) Table 108. North America Vulvar and Vaginal Atrophy Therapy Sales Price by Type (2027-2032) & (US$/Unit) Table 109. North America Vulvar and Vaginal Atrophy Therapy Revenue by Application (2021-2026) & (US$ Million) Table 110. North America Vulvar and Vaginal Atrophy Therapy Revenue by Application (2027-2032) & (US$ Million) Table 111. North America Vulvar and Vaginal Atrophy Therapy Sales by Application (2021-2026) & (K Units) Table 112. North America Vulvar and Vaginal Atrophy Therapy Sales by Application (2027-2032) & (K Units) Table 113. North America Vulvar and Vaginal Atrophy Therapy Sales Price by Application (2021-2026) & (US$/Unit) Table 114. North America Vulvar and Vaginal Atrophy Therapy Sales Price by Application (2027-2032) & (US$/Unit) Table 115. North America Vulvar and Vaginal Atrophy Therapy Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 116. North America Vulvar and Vaginal Atrophy Therapy Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 117. North America Vulvar and Vaginal Atrophy Therapy Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 118. North America Vulvar and Vaginal Atrophy Therapy Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 119. North America Vulvar and Vaginal Atrophy Therapy Sales by Country (2021-2026) & (K Units) Table 120. North America Vulvar and Vaginal Atrophy Therapy Sales by Country (2027-2032) & (K Units) Table 121. North America Vulvar and Vaginal Atrophy Therapy Sales Price by Country (2021-2026) & (US$/Unit) Table 122. North America Vulvar and Vaginal Atrophy Therapy Sales Price by Country (2027-2032) & (US$/Unit) Table 123. United States Vulvar and Vaginal Atrophy Therapy Revenue (2021-2032) & (US$ Million) Table 124. Canada Vulvar and Vaginal Atrophy Therapy Revenue (2021-2032) & (US$ Million) Table 125. Europe Vulvar and Vaginal Atrophy Therapy Revenue by Type (2021-2026) & (US$ Million) Table 126. Europe Vulvar and Vaginal Atrophy Therapy Revenue by Type (2027-2032) & (US$ Million) Table 127. Europe Vulvar and Vaginal Atrophy Therapy Sales by Type (2021-2026) & (K Units) Table 128. Europe Vulvar and Vaginal Atrophy Therapy Sales by Type (2027-2032) & (K Units) Table 129. Europe Vulvar and Vaginal Atrophy Therapy Sales Price by Type (2021-2026) & (US$/Unit) Table 130. Europe Vulvar and Vaginal Atrophy Therapy Sales Price by Type (2027-2032) & (US$/Unit) Table 131. Europe Vulvar and Vaginal Atrophy Therapy Revenue by Application (2021-2026) & (US$ Million) Table 132. Europe Vulvar and Vaginal Atrophy Therapy Revenue by Application (2027-2032) & (US$ Million) Table 133. Europe Vulvar and Vaginal Atrophy Therapy Sales by Application (2021-2026) & (K Units) Table 134. Europe Vulvar and Vaginal Atrophy Therapy Sales by Application (2027-2032) & (K Units) Table 135. Europe Vulvar and Vaginal Atrophy Therapy Sales Price by Application (2021-2026) & (US$/Unit) Table 136. Europe Vulvar and Vaginal Atrophy Therapy Sales Price by Application (2027-2032) & (US$/Unit) Table 137. Europe Vulvar and Vaginal Atrophy Therapy Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 138. Europe Vulvar and Vaginal Atrophy Therapy Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 139. Europe Vulvar and Vaginal Atrophy Therapy Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 140. Europe Vulvar and Vaginal Atrophy Therapy Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 141. Europe Vulvar and Vaginal Atrophy Therapy Sales by Country (2021-2026) & (K Units) Table 142. Europe Vulvar and Vaginal Atrophy Therapy Sales by Country (2027-2032) & (K Units) Table 143. Europe Vulvar and Vaginal Atrophy Therapy Sales Price by Country (2021-2026) & (US$/Unit) Table 144. Europe Vulvar and Vaginal Atrophy Therapy Sales Price by Country (2027-2032) & (US$/Unit) Table 145. Germany Vulvar and Vaginal Atrophy Therapy Revenue (2021-2032) & (US$ Million) Table 146. France Vulvar and Vaginal Atrophy Therapy Revenue (2021-2032) & (US$ Million) Table 147. U.K. Vulvar and Vaginal Atrophy Therapy Revenue (2021-2032) & (US$ Million) Table 148. Italy Vulvar and Vaginal Atrophy Therapy Revenue (2021-2032) & (US$ Million) Table 149. Netherlands Vulvar and Vaginal Atrophy Therapy Revenue (2021-2032) & (US$ Million) Table 150. Nordic Countries Vulvar and Vaginal Atrophy Therapy Revenue (2021-2032) & (US$ Million) Table 151. China Vulvar and Vaginal Atrophy Therapy Revenue by Type (2021-2026) & (US$ Million) Table 152. China Vulvar and Vaginal Atrophy Therapy Revenue by Type (2027-2032) & (US$ Million) Table 153. China Vulvar and Vaginal Atrophy Therapy Sales by Type (2021-2026) & (K Units) Table 154. China Vulvar and Vaginal Atrophy Therapy Sales by Type (2027-2032) & (K Units) Table 155. China Vulvar and Vaginal Atrophy Therapy Sales Price by Type (2021-2026) & (US$/Unit) Table 156. China Vulvar and Vaginal Atrophy Therapy Sales Price by Type (2027-2032) & (US$/Unit) Table 157. China Vulvar and Vaginal Atrophy Therapy Revenue by Application (2021-2026) & (US$ Million) Table 158. China Vulvar and Vaginal Atrophy Therapy Revenue by Application (2027-2032) & (US$ Million) Table 159. China Vulvar and Vaginal Atrophy Therapy Sales by Application (2021-2026) & (K Units) Table 160. China Vulvar and Vaginal Atrophy Therapy Sales by Application (2027-2032) & (K Units) Table 161. China Vulvar and Vaginal Atrophy Therapy Sales Price by Application (2021-2026) & (US$/Unit) Table 162. China Vulvar and Vaginal Atrophy Therapy Sales Price by Application (2027-2032) & (US$/Unit) Table 163. Asia Vulvar and Vaginal Atrophy Therapy Revenue by Type (2021-2026) & (US$ Million) Table 164. Asia Vulvar and Vaginal Atrophy Therapy Revenue by Type (2027-2032) & (US$ Million) Table 165. Asia Vulvar and Vaginal Atrophy Therapy Sales by Type (2021-2026) & (K Units) Table 166. Asia Vulvar and Vaginal Atrophy Therapy Sales by Type (2027-2032) & (K Units) Table 167. Asia Vulvar and Vaginal Atrophy Therapy Sales Price by Type (2021-2026) & (US$/Unit) Table 168. Asia Vulvar and Vaginal Atrophy Therapy Sales Price by Type (2027-2032) & (US$/Unit) Table 169. Asia Vulvar and Vaginal Atrophy Therapy Revenue by Application (2021-2026) & (US$ Million) Table 170. Asia Vulvar and Vaginal Atrophy Therapy Revenue by Application (2027-2032) & (US$ Million) Table 171. Asia Vulvar and Vaginal Atrophy Therapy Sales by Application (2021-2026) & (K Units) Table 172. Asia Vulvar and Vaginal Atrophy Therapy Sales by Application (2027-2032) & (K Units) Table 173. Asia Vulvar and Vaginal Atrophy Therapy Sales Price by Application (2021-2026) & (US$/Unit) Table 174. Asia Vulvar and Vaginal Atrophy Therapy Sales Price by Application (2027-2032) & (US$/Unit) Table 175. Asia Vulvar and Vaginal Atrophy Therapy Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 176. Asia Vulvar and Vaginal Atrophy Therapy Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 177. Asia Vulvar and Vaginal Atrophy Therapy Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 178. Asia Vulvar and Vaginal Atrophy Therapy Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 179. Asia Vulvar and Vaginal Atrophy Therapy Sales by Country (2021-2026) & (K Units) Table 180. Asia Vulvar and Vaginal Atrophy Therapy Sales by Country (2027-2032) & (K Units) Table 181. Asia Vulvar and Vaginal Atrophy Therapy Sales Price by Country (2021-2026) & (US$/Unit) Table 182. Asia Vulvar and Vaginal Atrophy Therapy Sales Price by Country (2027-2032) & (US$/Unit) Table 183. Japan Vulvar and Vaginal Atrophy Therapy Revenue (2021-2032) & (US$ Million) Table 184. South Korea Vulvar and Vaginal Atrophy Therapy Revenue (2021-2032) & (US$ Million) Table 185. India Vulvar and Vaginal Atrophy Therapy Revenue (2021-2032) & (US$ Million) Table 186. Australia Vulvar and Vaginal Atrophy Therapy Revenue (2021-2032) & (US$ Million) Table 187. China Taiwan Vulvar and Vaginal Atrophy Therapy Revenue (2021-2032) & (US$ Million) Table 188. Southeast Asia Vulvar and Vaginal Atrophy Therapy Revenue (2021-2032) & (US$ Million) Table 189. SAMEA Vulvar and Vaginal Atrophy Therapy Revenue by Type (2021-2026) & (US$ Million) Table 190. SAMEA Vulvar and Vaginal Atrophy Therapy Revenue by Type (2027-2032) & (US$ Million) Table 191. SAMEA Vulvar and Vaginal Atrophy Therapy Sales by Type (2021-2026) & (K Units) Table 192. SAMEA Vulvar and Vaginal Atrophy Therapy Sales by Type (2027-2032) & (K Units) Table 193. SAMEA Vulvar and Vaginal Atrophy Therapy Sales Price by Type (2021-2026) & (US$/Unit) Table 194. SAMEA Vulvar and Vaginal Atrophy Therapy Sales Price by Type (2027-2032) & (US$/Unit) Table 195. SAMEA Vulvar and Vaginal Atrophy Therapy Revenue by Application (2021-2026) & (US$ Million) Table 196. SAMEA Vulvar and Vaginal Atrophy Therapy Revenue by Application (2027-2032) & (US$ Million) Table 197. SAMEA Vulvar and Vaginal Atrophy Therapy Sales by Application (2021-2026) & (K Units) Table 198. SAMEA Vulvar and Vaginal Atrophy Therapy Sales by Application (2027-2032) & (K Units) Table 199. SAMEA Vulvar and Vaginal Atrophy Therapy Sales Price by Application (2021-2026) & (US$/Unit) Table 200. SAMEA Vulvar and Vaginal Atrophy Therapy Sales Price by Application (2027-2032) & (US$/Unit) Table 201. SAMEA Vulvar and Vaginal Atrophy Therapy Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 202. SAMEA Vulvar and Vaginal Atrophy Therapy Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 203. SAMEA Vulvar and Vaginal Atrophy Therapy Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 204. SAMEA Vulvar and Vaginal Atrophy Therapy Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 205. SAMEA Vulvar and Vaginal Atrophy Therapy Sales by Country (2021-2026) & (K Units) Table 206. SAMEA Vulvar and Vaginal Atrophy Therapy Sales by Country (2027-2032) & (K Units) Table 207. SAMEA Vulvar and Vaginal Atrophy Therapy Sales Price by Country (2021-2026) & (US$/Unit) Table 208. SAMEA Vulvar and Vaginal Atrophy Therapy Sales Price by Country (2027-2032) & (US$/Unit) Table 209. Brazil Vulvar and Vaginal Atrophy Therapy Revenue (2021-2032) & (US$ Million) Table 210. Argentina Vulvar and Vaginal Atrophy Therapy Revenue (2021-2032) & (US$ Million) Table 211. Chile Vulvar and Vaginal Atrophy Therapy Revenue (2021-2032) & (US$ Million) Table 212. Colombia Vulvar and Vaginal Atrophy Therapy Revenue (2021-2032) & (US$ Million) Table 213. Peru Vulvar and Vaginal Atrophy Therapy Revenue (2021-2032) & (US$ Million) Table 214. Saudi Arabia Vulvar and Vaginal Atrophy Therapy Revenue (2021-2032) & (US$ Million) Table 215. Israel Vulvar and Vaginal Atrophy Therapy Revenue (2021-2032) & (US$ Million) Table 216. UAE Vulvar and Vaginal Atrophy Therapy Revenue (2021-2032) & (US$ Million) Table 217. Turkey Vulvar and Vaginal Atrophy Therapy Revenue (2021-2032) & (US$ Million) Table 218. Iran Vulvar and Vaginal Atrophy Therapy Revenue (2021-2032) & (US$ Million) Table 219. Egypt Vulvar and Vaginal Atrophy Therapy Revenue (2021-2032) & (US$ Million) Table 220. Key Raw Materials Table 221. Raw Materials Key Suppliers Table 222. Vulvar and Vaginal Atrophy Therapy Distributors List Table 223. Vulvar and Vaginal Atrophy Therapy Customers List Table 224. Research Programs/Design for This Report Table 225. Authors List of This Report Table 226. Secondary Sources Table 227. Primary Sources List of Figures Figure 1. Vulvar and Vaginal Atrophy Therapy Image Figure 2. Global Vulvar and Vaginal Atrophy Therapy Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Vulvar and Vaginal Atrophy Therapy Market Size Share 2021 VS 2025 VS 2032 Figure 4. Vulvar Atrophy Therapy Image Figure 5. Vaginal Atrophy Therapy Image Figure 6. Global Vulvar and Vaginal Atrophy Therapy Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 7. Global Vulvar and Vaginal Atrophy Therapy Market Size Share 2021 VS 2025 VS 2032 Figure 8. Specialty Clinics Image Figure 9. Hospitals Image Figure 10. Ambulatory Surgical Centers Image Figure 11. Others Image Figure 12. Global Vulvar and Vaginal Atrophy Therapy Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 13. Global Vulvar and Vaginal Atrophy Therapy Revenue (2021-2032) & (US$ Million) Figure 14. Global Vulvar and Vaginal Atrophy Therapy Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 15. Global Vulvar and Vaginal Atrophy Therapy Revenue Market Share by Region: 2025 Versus 2032 Figure 16. Global Vulvar and Vaginal Atrophy Therapy Revenue Market Share by Region (2021-2032) Figure 17. Global Vulvar and Vaginal Atrophy Therapy Sales (2021-2032) & (K Units) Figure 18. Global Vulvar and Vaginal Atrophy Therapy Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 19. Global Vulvar and Vaginal Atrophy Therapy Sales Market Share by Region (2021-2032) Figure 20. US & Canada & Mexico Vulvar and Vaginal Atrophy Therapy Sales YoY (2021-2032) & (K Units) Figure 21. Europe Vulvar and Vaginal Atrophy Therapy Sales YoY (2021-2032) & (K Units) Figure 22. China Vulvar and Vaginal Atrophy Therapy Sales YoY (2021-2032) & (K Units) Figure 23. Asia (Excluding China) Vulvar and Vaginal Atrophy Therapy Sales YoY (2021-2032) & (K Units) Figure 24. South America, Middle East and Africa Vulvar and Vaginal Atrophy Therapy Sales YoY (2021-2032) & (K Units) Figure 25. Global Vulvar and Vaginal Atrophy Therapy Manufacturers Revenue Share Top 10 and Top 5 in 2025 Figure 26. Global Vulvar and Vaginal Atrophy Therapy Manufacturers Sales Share Top 10 and Top 5 in 2025 Figure 27. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 28. Global Vulvar and Vaginal Atrophy Therapy Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 29. Global Vulvar and Vaginal Atrophy Therapy Revenue Market Share by Type 2021 VS 2025 VS 2032 Figure 30. Global Vulvar and Vaginal Atrophy Therapy Revenue Market Share by Type (2021-2032) Figure 31. Global Vulvar and Vaginal Atrophy Therapy Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 32. Global Vulvar and Vaginal Atrophy Therapy Sales Market Share by Type 2021 VS 2025 VS 2032 Figure 33. Global Vulvar and Vaginal Atrophy Therapy Sales Market Share by Type (2021-2032) Figure 34. Global Vulvar and Vaginal Atrophy Therapy Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 35. Global Vulvar and Vaginal Atrophy Therapy Revenue Market Share by Application 2021 VS 2025 VS 2032 Figure 36. Global Vulvar and Vaginal Atrophy Therapy Revenue Market Share by Application (2021-2032) Figure 37. Global Vulvar and Vaginal Atrophy Therapy Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 38. Global Vulvar and Vaginal Atrophy Therapy Sales Market Share by Application 2021 VS 2025 VS 2032 Figure 39. Global Vulvar and Vaginal Atrophy Therapy Sales Market Share by Application (2021-2032) Figure 40. North America Vulvar and Vaginal Atrophy Therapy Revenue Share by Type (2021-2032) Figure 41. North America Vulvar and Vaginal Atrophy Therapy Sales Share by Type (2021-2032) Figure 42. North America Vulvar and Vaginal Atrophy Therapy Revenue Share by Application (2021-2032) Figure 43. North America Vulvar and Vaginal Atrophy Therapy Sales Share by Application (2021-2032) Figure 44. North America Vulvar and Vaginal Atrophy Therapy Revenue Share by Country (2021-2032) Figure 45. North America Vulvar and Vaginal Atrophy Therapy Sales Share by Country (2021-2032) Figure 46. Europe Vulvar and Vaginal Atrophy Therapy Revenue Share by Type (2021-2032) Figure 47. Europe Vulvar and Vaginal Atrophy Therapy Sales Share by Type (2021-2032) Figure 48. Europe Vulvar and Vaginal Atrophy Therapy Revenue Share by Application (2021-2032) Figure 49. Europe Vulvar and Vaginal Atrophy Therapy Sales Share by Application (2021-2032) Figure 50. Europe Vulvar and Vaginal Atrophy Therapy Revenue Share by Country (2021-2032) Figure 51. Europe Vulvar and Vaginal Atrophy Therapy Sales Share by Country (2021-2032) Figure 52. China Vulvar and Vaginal Atrophy Therapy Revenue Share by Type (2021-2032) Figure 53. China Vulvar and Vaginal Atrophy Therapy Sales Share by Type (2021-2032) Figure 54. China Vulvar and Vaginal Atrophy Therapy Revenue Share by Application (2021-2032) Figure 55. China Vulvar and Vaginal Atrophy Therapy Sales Share by Application (2021-2032) Figure 56. Asia Vulvar and Vaginal Atrophy Therapy Revenue Share by Type (2021-2032) Figure 57. Asia Vulvar and Vaginal Atrophy Therapy Sales Share by Type (2021-2032) Figure 58. Asia Vulvar and Vaginal Atrophy Therapy Revenue Share by Application (2021-2032) Figure 59. Asia Vulvar and Vaginal Atrophy Therapy Sales Share by Application (2021-2032) Figure 60. Asia Vulvar and Vaginal Atrophy Therapy Revenue Share by Country (2021-2032) Figure 61. Asia Vulvar and Vaginal Atrophy Therapy Sales Share by Country (2021-2032) Figure 62. SAMEA Vulvar and Vaginal Atrophy Therapy Revenue Share by Type (2021-2032) Figure 63. SAMEA Vulvar and Vaginal Atrophy Therapy Sales Share by Type (2021-2032) Figure 64. SAMEA Vulvar and Vaginal Atrophy Therapy Revenue Share by Application (2021-2032) Figure 65. SAMEA Vulvar and Vaginal Atrophy Therapy Sales Share by Application (2021-2032) Figure 66. SAMEA Vulvar and Vaginal Atrophy Therapy Revenue Share by Country (2021-2032) Figure 67. SAMEA Vulvar and Vaginal Atrophy Therapy Sales Share by Country (2021-2032) Figure 68. Vulvar and Vaginal Atrophy Therapy Value Chain Figure 69. Manufacturing Cost Structure Figure 70. Vulvar and Vaginal Atrophy Therapy Production Mode & Process Figure 71. Direct Comparison with Distribution Share Figure 72. Distributors Profiles Figure 73. Years Considered Figure 74. Research Process Figure 75. Key Executives Interviewed

Scope & coverage.

Types
  • Vulvar Atrophy Therapy
  • Vaginal Atrophy Therapy
Applications
  • Specialty Clinics
  • Hospitals
  • Ambulatory Surgical Centers
  • Others
Companies covered
  • Viveve
  • VenusConcept
  • ThermiGen LLC
  • Lutronic
  • Hologic
  • Fotona
  • BTL Group of Companies
  • Almirall
  • Alma Lasers

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Vulvar and Vaginal Atrophy Therapy Market by Type
  3. 1.2.1 Global Vulvar and Vaginal Atrophy Therapy Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Vulvar Atrophy Therapy
  5. 1.2.3 Vaginal Atrophy Therapy
  6. 1.3 Vulvar and Vaginal Atrophy Therapy Market by Application
  7. 1.3.1 Global Vulvar and Vaginal Atrophy Therapy Market Size by Application, 2021 VS 2025 VS 2032
  8. 1.3.2 Specialty Clinics
  9. 1.3.3 Hospitals
  10. 1.3.4 Ambulatory Surgical Centers
  11. 1.3.5 Others
  12. 1.4 Assumptions and Limitations
  13. 1.5 Study Goals and Objectives
2 Vulvar and Vaginal Atrophy Therapy Market Dynamics
  1. 2.1 Vulvar and Vaginal Atrophy Therapy Industry Trends
  2. 2.2 Vulvar and Vaginal Atrophy Therapy Industry Drivers
  3. 2.3 Vulvar and Vaginal Atrophy Therapy Industry Opportunities and Challenges
  4. 2.4 Vulvar and Vaginal Atrophy Therapy Industry Restraints
3 Global Market Growth Prospects
  1. 3.1 Global Vulvar and Vaginal Atrophy Therapy Revenue Estimates and Forecasts (2021-2032)
  2. 3.2 Global Vulvar and Vaginal Atrophy Therapy Revenue by Region
  3. 3.2.1 Global Vulvar and Vaginal Atrophy Therapy Revenue by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Vulvar and Vaginal Atrophy Therapy Revenue by Region (2021-2026)
  5. 3.2.3 Global Vulvar and Vaginal Atrophy Therapy Revenue by Region (2027-2032)
  6. 3.2.4 Global Vulvar and Vaginal Atrophy Therapy Revenue Market Share by Region (2021-2032)
  7. 3.3 Global Vulvar and Vaginal Atrophy Therapy Sales Estimates and Forecasts 2021-2032
  8. 3.4 Global Vulvar and Vaginal Atrophy Therapy Sales by Region
  9. 3.4.1 Global Vulvar and Vaginal Atrophy Therapy Sales by Region: 2021 VS 2025 VS 2032
  10. 3.4.2 Global Vulvar and Vaginal Atrophy Therapy Sales by Region (2021-2026)
  11. 3.4.3 Global Vulvar and Vaginal Atrophy Therapy Sales by Region (2027-2032)
  12. 3.4.4 Global Vulvar and Vaginal Atrophy Therapy Sales Market Share by Region (2021-2032)
  13. 3.5 US & Canada & Mexico
  14. 3.6 Europe
  15. 3.7 China
  16. 3.8 Asia (Excluding China)
  17. 3.9 South America, Middle East and Africa
4 Market Competitive Landscape by Manufacturers
  1. 4.1 Global Vulvar and Vaginal Atrophy Therapy Revenue by Manufacturers
  2. 4.1.1 Global Vulvar and Vaginal Atrophy Therapy Revenue by Manufacturers (2021-2026)
  3. 4.1.2 Global Vulvar and Vaginal Atrophy Therapy Revenue Market Share by Manufacturers (2021-2026)
  4. 4.1.3 Global Vulvar and Vaginal Atrophy Therapy Manufacturers Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Vulvar and Vaginal Atrophy Therapy Sales by Manufacturers
  6. 4.2.1 Global Vulvar and Vaginal Atrophy Therapy Sales by Manufacturers (2021-2026)
  7. 4.2.2 Global Vulvar and Vaginal Atrophy Therapy Sales Market Share by Manufacturers (2021-2026)
  8. 4.2.3 Global Vulvar and Vaginal Atrophy Therapy Manufacturers Sales Share Top 10 and Top 5 in 2025
  9. 4.3 Global Vulvar and Vaginal Atrophy Therapy Sales Price by Manufacturers (2021-2026)
  10. 4.4 Global Vulvar and Vaginal Atrophy Therapy Key Manufacturers Ranking, 2024 VS 2025 VS 2026
  11. 4.5 Global Vulvar and Vaginal Atrophy Therapy Key Manufacturers Manufacturing Sites & Headquarters
  12. 4.6 Global Vulvar and Vaginal Atrophy Therapy Manufacturers, Product Type & Application
  13. 4.7 Global Vulvar and Vaginal Atrophy Therapy Manufacturers' Establishment Date
  14. 4.8 Market Competitive Analysis
  15. 4.8.1 Global Vulvar and Vaginal Atrophy Therapy Market CR5 and HHI
  16. 4.8.2 2025 Vulvar and Vaginal Atrophy Therapy Tier 1, Tier 2, and Tier 3
5 Vulvar and Vaginal Atrophy Therapy Market by Type
  1. 5.1 Global Vulvar and Vaginal Atrophy Therapy Revenue by Type
  2. 5.1.1 Global Vulvar and Vaginal Atrophy Therapy Revenue by Type (2021 VS 2025 VS 2032)
  3. 5.1.2 Global Vulvar and Vaginal Atrophy Therapy Revenue by Type (2021-2032) & (US$ Million)
  4. 5.1.3 Global Vulvar and Vaginal Atrophy Therapy Revenue Market Share by Type (2021-2032)
  5. 5.2 Global Vulvar and Vaginal Atrophy Therapy Sales by Type
  6. 5.2.1 Global Vulvar and Vaginal Atrophy Therapy Sales by Type (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Vulvar and Vaginal Atrophy Therapy Sales by Type (2021-2032) & (K Units)
  8. 5.2.3 Global Vulvar and Vaginal Atrophy Therapy Sales Market Share by Type (2021-2032)
  9. 5.3 Global Vulvar and Vaginal Atrophy Therapy Price by Type
6 Vulvar and Vaginal Atrophy Therapy Market by Application
  1. 6.1 Global Vulvar and Vaginal Atrophy Therapy Revenue by Application
  2. 6.1.1 Global Vulvar and Vaginal Atrophy Therapy Revenue by Application (2021 VS 2025 VS 2032)
  3. 6.1.2 Global Vulvar and Vaginal Atrophy Therapy Revenue by Application (2021-2032) & (US$ Million)
  4. 6.1.3 Global Vulvar and Vaginal Atrophy Therapy Revenue Market Share by Application (2021-2032)
  5. 6.2 Global Vulvar and Vaginal Atrophy Therapy Sales by Application
  6. 6.2.1 Global Vulvar and Vaginal Atrophy Therapy Sales by Application (2021 VS 2025 VS 2032)
  7. 6.2.2 Global Vulvar and Vaginal Atrophy Therapy Sales by Application (2021-2032) & (K Units)
  8. 6.2.3 Global Vulvar and Vaginal Atrophy Therapy Sales Market Share by Application (2021-2032)
  9. 6.3 Global Vulvar and Vaginal Atrophy Therapy Price by Application
7 Company Profiles
  1. 7.1 Viveve
  2. 7.1.1 Viveve Company Information
  3. 7.1.2 Viveve Business Overview
  4. 7.1.3 Viveve Vulvar and Vaginal Atrophy Therapy Sales, Revenue, Price and Gross Margin (2021-2026)
  5. 7.1.4 Viveve Vulvar and Vaginal Atrophy Therapy Product Portfolio
  6. 7.1.5 Viveve Recent Developments
  7. 7.2 VenusConcept
  8. 7.2.1 VenusConcept Company Information
  9. 7.2.2 VenusConcept Business Overview
  10. 7.2.3 VenusConcept Vulvar and Vaginal Atrophy Therapy Sales, Revenue, Price and Gross Margin (2021-2026)
  11. 7.2.4 VenusConcept Vulvar and Vaginal Atrophy Therapy Product Portfolio
  12. 7.2.5 VenusConcept Recent Developments
  13. 7.3 ThermiGen LLC
  14. 7.3.1 ThermiGen LLC Company Information
  15. 7.3.2 ThermiGen LLC Business Overview
  16. 7.3.3 ThermiGen LLC Vulvar and Vaginal Atrophy Therapy Sales, Revenue, Price and Gross Margin (2021-2026)
  17. 7.3.4 ThermiGen LLC Vulvar and Vaginal Atrophy Therapy Product Portfolio
  18. 7.3.5 ThermiGen LLC Recent Developments
  19. 7.4 Lutronic
  20. 7.4.1 Lutronic Company Information
  21. 7.4.2 Lutronic Business Overview
  22. 7.4.3 Lutronic Vulvar and Vaginal Atrophy Therapy Sales, Revenue, Price and Gross Margin (2021-2026)
  23. 7.4.4 Lutronic Vulvar and Vaginal Atrophy Therapy Product Portfolio
  24. 7.4.5 Lutronic Recent Developments
  25. 7.5 Hologic
  26. 7.5.1 Hologic Company Information
  27. 7.5.2 Hologic Business Overview
  28. 7.5.3 Hologic Vulvar and Vaginal Atrophy Therapy Sales, Revenue, Price and Gross Margin (2021-2026)
  29. 7.5.4 Hologic Vulvar and Vaginal Atrophy Therapy Product Portfolio
  30. 7.5.5 Hologic Recent Developments
  31. 7.6 Fotona
  32. 7.6.1 Fotona Company Information
  33. 7.6.2 Fotona Business Overview
  34. 7.6.3 Fotona Vulvar and Vaginal Atrophy Therapy Sales, Revenue, Price and Gross Margin (2021-2026)
  35. 7.6.4 Fotona Vulvar and Vaginal Atrophy Therapy Product Portfolio
  36. 7.6.5 Fotona Recent Developments
  37. 7.7 BTL Group of Companies
  38. 7.7.1 BTL Group of Companies Company Information
  39. 7.7.2 BTL Group of Companies Business Overview
  40. 7.7.3 BTL Group of Companies Vulvar and Vaginal Atrophy Therapy Sales, Revenue, Price and Gross Margin (2021-2026)
  41. 7.7.4 BTL Group of Companies Vulvar and Vaginal Atrophy Therapy Product Portfolio
  42. 7.7.5 BTL Group of Companies Recent Developments
  43. 7.8 Almirall
  44. 7.8.1 Almirall Company Information
  45. 7.8.2 Almirall Business Overview
  46. 7.8.3 Almirall Vulvar and Vaginal Atrophy Therapy Sales, Revenue, Price and Gross Margin (2021-2026)
  47. 7.8.4 Almirall Vulvar and Vaginal Atrophy Therapy Product Portfolio
  48. 7.8.5 Almirall Recent Developments
  49. 7.9 Alma Lasers
  50. 7.9.1 Alma Lasers Company Information
  51. 7.9.2 Alma Lasers Business Overview
  52. 7.9.3 Alma Lasers Vulvar and Vaginal Atrophy Therapy Sales, Revenue, Price and Gross Margin (2021-2026)
  53. 7.9.4 Alma Lasers Vulvar and Vaginal Atrophy Therapy Product Portfolio
  54. 7.9.5 Alma Lasers Recent Developments
8 North America
  1. 8.1 North America Vulvar and Vaginal Atrophy Therapy Market Size by Type
  2. 8.1.1 North America Vulvar and Vaginal Atrophy Therapy Revenue by Type (2021-2032)
  3. 8.1.2 North America Vulvar and Vaginal Atrophy Therapy Sales by Type (2021-2032)
  4. 8.1.3 North America Vulvar and Vaginal Atrophy Therapy Price by Type (2021-2032)
  5. 8.2 North America Vulvar and Vaginal Atrophy Therapy Market Size by Application
  6. 8.2.1 North America Vulvar and Vaginal Atrophy Therapy Revenue by Application (2021-2032)
  7. 8.2.2 North America Vulvar and Vaginal Atrophy Therapy Sales by Application (2021-2032)
  8. 8.2.3 North America Vulvar and Vaginal Atrophy Therapy Price by Application (2021-2032)
  9. 8.3 North America Vulvar and Vaginal Atrophy Therapy Market Size by Country
  10. 8.3.1 North America Vulvar and Vaginal Atrophy Therapy Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 8.3.2 North America Vulvar and Vaginal Atrophy Therapy Sales by Country (2021 VS 2025 VS 2032)
  12. 8.3.3 North America Vulvar and Vaginal Atrophy Therapy Price by Country (2021-2032)
  13. 8.3.4 United States
  14. 8.3.5 Canada
9 Europe
  1. 9.1 Europe Vulvar and Vaginal Atrophy Therapy Market Size by Type
  2. 9.1.1 Europe Vulvar and Vaginal Atrophy Therapy Revenue by Type (2021-2032)
  3. 9.1.2 Europe Vulvar and Vaginal Atrophy Therapy Sales by Type (2021-2032)
  4. 9.1.3 Europe Vulvar and Vaginal Atrophy Therapy Price by Type (2021-2032)
  5. 9.2 Europe Vulvar and Vaginal Atrophy Therapy Market Size by Application
  6. 9.2.1 Europe Vulvar and Vaginal Atrophy Therapy Revenue by Application (2021-2032)
  7. 9.2.2 Europe Vulvar and Vaginal Atrophy Therapy Sales by Application (2021-2032)
  8. 9.2.3 Europe Vulvar and Vaginal Atrophy Therapy Price by Application (2021-2032)
  9. 9.3 Europe Vulvar and Vaginal Atrophy Therapy Market Size by Country
  10. 9.3.1 Europe Vulvar and Vaginal Atrophy Therapy Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 9.3.2 Europe Vulvar and Vaginal Atrophy Therapy Sales by Country (2021 VS 2025 VS 2032)
  12. 9.3.3 Europe Vulvar and Vaginal Atrophy Therapy Price by Country (2021-2032)
  13. 9.3.4 Germany
  14. 9.3.5 France
  15. 9.3.6 U.K.
  16. 9.3.7 Italy
  17. 9.3.8 Netherlands
  18. 9.3.9 Nordic Countries
10 China
  1. 10.1 China Vulvar and Vaginal Atrophy Therapy Market Size by Type
  2. 10.1.1 China Vulvar and Vaginal Atrophy Therapy Revenue by Type (2021-2032)
  3. 10.1.2 China Vulvar and Vaginal Atrophy Therapy Sales by Type (2021-2032)
  4. 10.1.3 China Vulvar and Vaginal Atrophy Therapy Price by Type (2021-2032)
  5. 10.2 China Vulvar and Vaginal Atrophy Therapy Market Size by Application
  6. 10.2.1 China Vulvar and Vaginal Atrophy Therapy Revenue by Application (2021-2032)
  7. 10.2.2 China Vulvar and Vaginal Atrophy Therapy Sales by Application (2021-2032)
  8. 10.2.3 China Vulvar and Vaginal Atrophy Therapy Price by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Vulvar and Vaginal Atrophy Therapy Market Size by Type
  2. 11.1.1 Asia Vulvar and Vaginal Atrophy Therapy Revenue by Type (2021-2032)
  3. 11.1.2 Asia Vulvar and Vaginal Atrophy Therapy Sales by Type (2021-2032)
  4. 11.1.3 Asia Vulvar and Vaginal Atrophy Therapy Price by Type (2021-2032)
  5. 11.2 Asia Vulvar and Vaginal Atrophy Therapy Market Size by Application
  6. 11.2.1 Asia Vulvar and Vaginal Atrophy Therapy Revenue by Application (2021-2032)
  7. 11.2.2 Asia Vulvar and Vaginal Atrophy Therapy Sales by Application (2021-2032)
  8. 11.2.3 Asia Vulvar and Vaginal Atrophy Therapy Price by Application (2021-2032)
  9. 11.3 Asia Vulvar and Vaginal Atrophy Therapy Market Size by Country
  10. 11.3.1 Asia Vulvar and Vaginal Atrophy Therapy Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 11.3.2 Asia Vulvar and Vaginal Atrophy Therapy Sales by Country (2021 VS 2025 VS 2032)
  12. 11.3.3 Asia Vulvar and Vaginal Atrophy Therapy Price by Country (2021-2032)
  13. 11.3.4 Japan
  14. 11.3.5 South Korea
  15. 11.3.6 India
  16. 11.3.7 Australia
  17. 11.3.8 Taiwan
  18. 11.3.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Vulvar and Vaginal Atrophy Therapy Market Size by Type
  2. 12.1.1 SAMEA Vulvar and Vaginal Atrophy Therapy Revenue by Type (2021-2032)
  3. 12.1.2 SAMEA Vulvar and Vaginal Atrophy Therapy Sales by Type (2021-2032)
  4. 12.1.3 SAMEA Vulvar and Vaginal Atrophy Therapy Price by Type (2021-2032)
  5. 12.2 SAMEA Vulvar and Vaginal Atrophy Therapy Market Size by Application
  6. 12.2.1 SAMEA Vulvar and Vaginal Atrophy Therapy Revenue by Application (2021-2032)
  7. 12.2.2 SAMEA Vulvar and Vaginal Atrophy Therapy Sales by Application (2021-2032)
  8. 12.2.3 SAMEA Vulvar and Vaginal Atrophy Therapy Price by Application (2021-2032)
  9. 12.3 SAMEA Vulvar and Vaginal Atrophy Therapy Market Size by Country
  10. 12.3.1 SAMEA Vulvar and Vaginal Atrophy Therapy Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 12.3.2 SAMEA Vulvar and Vaginal Atrophy Therapy Sales by Country (2021 VS 2025 VS 2032)
  12. 12.3.3 SAMEA Vulvar and Vaginal Atrophy Therapy Price by Country (2021-2032)
  13. 12.3.4 Brazil
  14. 12.3.5 Argentina
  15. 12.3.6 Chile
  16. 12.3.7 Colombia
  17. 12.3.8 Peru
  18. 12.3.9 Saudi Arabia
  19. 12.3.10 Israel
  20. 12.3.11 UAE
  21. 12.3.12 Turkey
  22. 12.3.13 Iran
  23. 12.3.14 Egypt
13 Value Chain and Sales Channels Analysis
  1. 13.1 Vulvar and Vaginal Atrophy Therapy Value Chain Analysis
  2. 13.1.1 Vulvar and Vaginal Atrophy Therapy Key Raw Materials
  3. 13.1.2 Raw Materials Key Suppliers
  4. 13.1.3 Manufacturing Cost Structure
  5. 13.1.4 Vulvar and Vaginal Atrophy Therapy Production Mode & Process
  6. 13.2 Vulvar and Vaginal Atrophy Therapy Sales Channels Analysis
  7. 13.2.1 Direct Comparison with Distribution Share
  8. 13.2.2 Vulvar and Vaginal Atrophy Therapy Distributors
  9. 13.2.3 Vulvar and Vaginal Atrophy Therapy Customers
14 Concluding Insights
    15 Appendix
    1. 15.1 Reasons for Doing This Study
    2. 15.2 Research Methodology
    3. 15.3 Research Process
    4. 15.4 Authors List of This Report
    5. 15.5 Data Source
    6. 15.5.1 Secondary Sources
    7. 15.5.2 Primary Sources
    8. 15.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst